Hologen
Category: AI in Biotech / Drug Discovery
Clinical-stage AI biotech co-founded by Eric Schmidt building 'Large Medicine Models' — multimodal generative AI trained on clinical and real-world patient data to de-risk and optimize drug development. Hologen was founded in 2023. The company is led by Roland W. Tegeder, PhD. Based in St Peter Port, Guernsey. Team size: 11-50. Latest round: Series A. Key investors include Averin (Series A lead / partnered 2025), 2468 Ventures, Gaingels, Mana Ventures, Menon VC, SW7 Group, Eric Schmidt, Singular Link, JSL Health Capital.
- Founded
- 2023
- Headquarters
- St Peter Port, Guernsey
- Team size
- 11-50
Value proposition
Uses large-scale, multi-modal generative AI foundation models (Large Medicine Models) trained on clinical and real-world data to improve the design, evaluation, and success rate of late-stage clinical trials, reducing the cost and risk of bringing new treatments to market.
Products and solutions
Large Medicine Models (LMMs) — multimodal generative foundation models combining biomedical, clinical trial, and real-world patient data, Co-development/co-investment vehicles for late-stage clinical assets (e.g., Reogen Limited JV with MeiraGTx for neurological gene therapies)
Unique value
Combines Google-scale AI leadership (Eric Schmidt) with deep clinical/biomedical academic ties (UCL, King's College London, Imperial College London) and a direct co-investment model in clinical assets, differentiating from pure AI-software drug discovery vendors.
Target customer
Pharmaceutical and biotech companies with clinical-stage drug assets (e.g., gene therapy developers) seeking to de-risk and accelerate trial design and execution.
Industries served
Biotech / Pharma, Clinical Trials, Drug Development, Neurology (Parkinson's), Gene Therapy
Technology advantage
Proprietary multimodal generative 'Large Medicine Model' architecture trained jointly on clinical trial and real-world patient data; spin-out academic pedigree from UCL/KCL; capital-intensive co-development model (invests directly in clinical assets rather than only licensing software/insights).
How they differentiate
Unlike discovery-stage AI drug design platforms (e.g., Insilico, Exscientia), Hologen focuses on late-stage clinical trial de-risking and directly co-funds/co-develops clinical assets (e.g., $230-430M JV with MeiraGTx) rather than purely licensing AI insights.
Main competitors
Insilico Medicine, Recursion Pharmaceuticals, Owkin / BenevolentAI / Valo Health (AI-driven drug discovery/development platforms)
Key partnerships
MeiraGTx — strategic collaboration; JV Reogen Limited (formerly Hologen Neuro AI Ltd; MeiraGTx ~30%) with up to $230–430M committed capital for Parkinson's AAV-GAD and obesity AAV-BDNF through commercialization; additional ~$95M upfront payment due from Hologen noted in MeiraGTx Q2 2026, Academic ties: UCL, King's College London, Imperial College London, Minority stake / funding contribution in MeiraGTx manufacturing subsidiary, NVIDIA / CoreWeave compute collaboration (Cambridge-1 foundation-model training)
Notable customers
MeiraGTx / Reogen Limited (strategic collaboration & JV partner — not a traditional SaaS customer; licenses + development services)
Major milestones
2023: Founded; spun out of UCL/KCL research, Mar 2025: Strategic collaboration with MeiraGTx; form JV Hologen Neuro AI (later Reogen) with up to $230–430M committed capital for AAV-GAD Parkinson's and AAV-BDNF obesity, Apr 2026: MeiraGTx–Hologen subscription / initial closing for Neuro JV (SEC 8-K), Jan 2026–present: Seeking $150M Series A at ~$850M pre-money (STAT); PitchBook still lists round In Progress as of Aug 2026, May 2026: Singular Link discloses strategic stake, Aug 2026: MeiraGTx Q2 confirms JV renamed Reogen Limited; Hologen AI used in AAV-GAD RMAT package; ~$95M additional upfront still due from Hologen
Market positioning
Well-capitalized, high-profile challenger in AI-driven clinical development, leveraging Eric Schmidt's brand and network; reported to be seeking a ~$150M Series A at ~$850M pre-money valuation (still in progress as of Aug 2026) while clinical-stage with a large MeiraGTx co-development JV.
Geographic focus
UK/Europe academic and biotech ecosystem with global (US-heavy) AI drug discovery competitive set.
About Roland W. Tegeder, PhD
Former Partner, Goldman Sachs (Managing Director, Tokyo, cross-asset structured products); Founding Partner, SW7 Group (technology investment/incubation firm); Chairman & Founding Partner, RAIN Foundation LBG. PhD.
Latest news about Hologen
More AI in Biotech / Drug Discovery companies
Official website: https://hologen.ai